|1.||Chey, William D: 8 articles (09/2011 - 01/2003)|
|2.||Talley, Nicholas J: 7 articles (08/2008 - 05/2002)|
|3.||Prous, J R: 7 articles (09/2007 - 01/2003)|
|4.||Rabasseda, X: 7 articles (09/2007 - 01/2003)|
|5.||Tack, Jan: 5 articles (03/2010 - 08/2002)|
|6.||Bayes, M: 5 articles (09/2007 - 05/2005)|
|7.||Earnest, David L: 4 articles (06/2010 - 11/2006)|
|8.||Pfannkuche, Hans-Juergen: 4 articles (10/2009 - 11/2004)|
|9.||Shetzline, Michael A: 4 articles (05/2008 - 11/2005)|
|10.||Tougas, G: 3 articles (02/2011 - 10/2002)|
02/01/2007 - "Tegaserod was effective for improving constipation in the overall study populations; no significant adverse events were noted. "
11/01/2004 - "In conclusion, treatment of chronic constipation with tegaserod was associated with significant improvement in bowel frequency as well as other constipation symptoms. "
01/01/2007 - "Ten studies evaluated the efficacy of tegaserod on global gastrointestinal (GI) symptoms in patients with constipation-predominant IBS (C-IBS). "
01/01/2004 - "Seven studies evaluated the efficacy of tegaserod on global gastrointestinal (GI) symptoms in patients with constipation-predominant IBS (C-IBS). "
09/01/1999 - "Oral tegaserod 2 (p < 0.05) or 6mg twice daily improved symptoms of abdominal discomfort, bloating and constipation (assessed using a Subjects' Global Assessment Scale) compared with placebo in patients with constipation-predominant IBS in a double-blind, dose-ranging study. "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
04/01/2005 - "Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome."
08/01/2002 - "Clinical trials show that tegaserod is effective and safe in the treatment of patients with irritable bowel syndrome. "
12/01/2004 - "Tegaserod has been safely employed in clinical trials where it has demonstrated efficacy in normalizing intestinal function, thereby improving irritable bowel syndrome symptoms."
04/01/2010 - "Comments on tegaserod trial on irritable bowel syndrome."
07/01/2007 - "Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study."
|3.||Abdominal Pain (Pain, Abdominal)
01/01/2004 - "Tegaserod did not significantly improve the patients' individual symptoms of abdominal pain and discomfort although bowel habit showed a statistically significant improvement with tegaserod 4 mg and there was a non-significant trend in favour of tegaserod 12 mg. When GI symptoms were assessed separately, those indicative of GI motility such as number of bowel movements and days without bowel movements were generally improved with tegaserod although the proportion of patients experiencing diarrhoea was significantly higher in the tegaserod 12 mg group compared with placebo (RR 2.75, 95% CI 1.90, 3.97), with a number needed to harm (NNH) of 20. "
11/01/2004 - "Patients who were treated with tegaserod had an overall improvement in IBS symptoms (Subject's Assessment of Global Relief) as well as in secondary end points, such as abdominal pain and discomfort, stool consistency, change in bowel movements and relief of bloating. "
01/01/2004 - "Tegaserod has been assessed in a number of international multicentre trials and its use leads to an improvement in abdominal pain and bowel dysfunction as well as global well-being, at the expense of remarkably few adverse effects. "
04/01/2003 - "In clinical trials with tegaserod, the Subject's Global Assessment (SGA) of Relief (a global measure that includes overall wellbeing, abdominal pain/discomfort, and bowel function) was used to identify responders. "
01/01/2008 - "In the group with other indications to start tegaserod therapy, moderate or significant relief of abdominal pain and bloating was noted in 64% and 68% of patients, respectively. "
01/01/2006 - "Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P < 0.05). "
04/01/2014 - "The 5-HT(4) receptor agonist tegaserod (TEG) has been reported to modulate visceral pain. "
08/01/2008 - "Tegaserod did not significantly alter balloon volume to pain (primary variable); however, pressure to gastric pain increased (p = 0.044 vs. placebo). "
04/01/2006 - "Tegaserod did not alter pain with acid infusion. "
04/01/2006 - "Tegaserod significantly increased balloon pressure to pain (P = .04) and the mean (P = .002) and maximum wall tension at pain (P = .0004). "
|5.||Parkinson Disease (Parkinson's Disease)
01/01/2007 - "Tegaserod in constipation associated with Parkinson disease."
01/01/2006 - "We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). "
01/01/2006 - "Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease."
01/01/2014 - "One trial in people with spinal cord injury showed statistically significant improvement in total bowel care time comparing intramuscular neostigmine-glycopyrrolate (anticholinesterase plus an anticholinergic drug) with placebo (MD 23.3 minutes, 95% CI 4.68 to 41.92).Five studies reported the use of cisapride and tegaserod in people with spinal cord injuries or Parkinson's disease. "
01/01/2013 - "One trial in people with spinal cord injury showed statistically significant improvement in total bowel care time comparing intramuscular neostigmine-glycopyrrolate (anticholinesterase plus an anticholinergic drug) with placebo (MD 23.3 minutes, 95% CI 4.68 to 41.92).Five studies reported the use of cisapride and tegaserod in people with spinal cord injuries or Parkinson's disease. "
|1.||Serotonin (5 Hydroxytryptamine)
|2.||5-HT4 Serotonin Receptors
|5.||Serotonin 5-HT4 Receptor Agonists
|7.||Glycopyrrolate (Glycopyrronium Bromide)
|8.||Neostigmine (Neostigmine Bromide)
|2.||Chinese Traditional Medicine (Traditional Chinese Medicine)
|4.||Renal Dialysis (Hemodialysis)